To include your compound in the COVID-19 Resource Center, submit it here.

Reviewers scrutinize Jardiance's CV efficacy data

FDA is asking an advisory committee to vote on whether data from a cardiovascular outcomes trial (CVOT) show diabetes drug Jardiance empagliflozin does not result in an unacceptable increase

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE